Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 9, 2000 - Issue 11
Submit an article Journal homepage
131
Views
44
CrossRef citations to date
0
Altmetric
Drug Evaluation

Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent

Michael H Davidson Nutrition and Metabolism Research Unit, Chicago Center for Clinical Research, 515 North State Street, Suite 2700, Chicago, IL 60610, USA. [email protected]
,
Mary R Dicklin Nutrition and Metabolism Research Unit, Chicago Center for Clinical Research, 515 North State Street, Suite 2700, Chicago, IL 60610, USA. [email protected]
,
Kevin C Maki Nutrition and Metabolism Research Unit, Chicago Center for Clinical Research, 515 North State Street, Suite 2700, Chicago, IL 60610, USA. [email protected]
&
Ruth M Kleinpell Nutrition and Metabolism Research Unit, Chicago Center for Clinical Research, 515 North State Street, Suite 2700, Chicago, IL 60610, USA. [email protected]
Pages 2663-2671 | Published online: 23 Feb 2005

Bibliography

  • GAZIANO JM, BEBERT PR, HENNEKENS CH: Cholesterol reduction: Weighing the benefits and risks. Ann. Int. Med. (1996) 124:914–918.
  • NATIONAL CHOLESTEROL EDUCATION PROGRAM EXPERT PANEL: Second report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Circulation (1994) 84:1329–1445.
  • BROWN V: Hypercholesterolemia in the United States: how far have we come? Am. J. Med. (1997) 102(2A):3–6.
  • BROWN G, ALBERS JJ, FISHER LD et al.: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipo-protein B. N Engl. J. Med. (1990) 323:1289–1298.
  • CASTELLI WP, OCKENE JK, ROBERTS WC: Cardiovascular risk reduction: What really works? Patient Care (1997) 47–60.
  • DOWNS J, CLEARFIELD M, WEIS S et al.: Primary preven-tion of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA (1998) 279:1615–1622.
  • LIPID RESEARCH CLINICS PROGRAM: The lip id Research Clinics Coronary Primary Prevention trial results I. Reduction in incidence of coronary heart disease. J Am. Med. Assoc. (1984) 251:351–364.
  • LIPID RESEARCH CLINICS PROGRAM: The lip id Research Clinics Coronary Primary Prevention trial results II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. j. Am. Med. Assoc. (1984) 151:365–374.
  • SACKS FM, PFEFFER MA, MOYE LA et al.: The effect ofpravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl. J. Med. (1996) 335:1001–1009.
  • SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandi-navian simvastatin survival study (4S). Lancet (1994) 344:1383–1389.
  • SHEPHERD J, COBBE SM, FORD I et al.: Prevention ofcoronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. EngI J. Med. (1995) 333:1301–1307.
  • THE LONG-TERM INTERVENTION WITH PRAVASTATININ ISCHAEMIC DISEASE (LIPID) STUDY GROUP: Preven-tion of cardiovascular events and death with pravas-tatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl. J Med. (1998) 339:1349–1357.
  • ANDRADE SE, WALKER AM, GOTTLIEB LK et al.: Discon-tinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings? N Engl. J. Med. (1995) 332:1125–1131.
  • AVORN, J, MONETTE J, LACOUR A et al: Persistence of use of lipid-lowering medications. JAMA (1998) 279:1458–1462.
  • FAERGEMAN 0: Challenges to best practice: Why are guidelines not implemented? Eur. Heart J (1999) 1 (Suppl.):J12–J16.
  • PEDERSEN TR: Aggressive lipid-lowering therapy: a clinical imperative. Eur. Heart J. (1998) M15–M21.
  • AMERICAN HEART ASSOCIATION SCIENCE ADVISORY TASK FORCE ON RISK REDUCTION: Guide to primary prevention of cardiovascular diseases. Circulation (1997) 95:2329–2331.
  • AQUILANI R, TRAMARIN R, PEDRETTI RF et al.: Despitegood compliance, very low fat diet alone does not achieve recommended cholesterol goals in outpatients with coronary heart disease. Eur. Heart J. (1999) 20:1020–1029.
  • FARMER JA, GOTTO AM: Choosing the right lipid-regulating agent. Drugs (1996) 52:649–661.
  • HUNNINGHAKE D: HMG-CoA reductase inhibitors. Curr. Opin. Lipidol (1992) 3:22–28.
  • HUNNINGHAKE DB, STEIN EA, BREMNER F et al.: Dose-response study of colestipol tablets in patients with moderate hypercholesterolemia. Am. J Therap. (1995) 2:180–189.
  • LYONS D, WEBSTER J, FOWLER G, PETRIE JC: Colestipol at varying dosage intervals in the treatment of moderate hypercholesterolaemia. Br. J. Clin. Pharmacol. (1994) 37:59–62.
  • GRUNDY SM, AHRENS EH, SALEN G: Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyr amine and ileal exclusion on cholesterol metabolism. J. Lab. Clin. Med. (1971) 178:94–121.
  • GRUNDY SM, BALADY GJ, CRIQUI MH et al: Guide to primary prevention of cardiovascular diseases. A statement for healthcare professionals from the task force on risk reduction. Circulation (1997) 95:2329–2331.
  • GOTTO A: Dyslipidemia and atherosclerosis. Circula-tion (1993) 87 (Suppl. III):111–54–111–59.
  • SPENCE D, HUFF M, HEIDENHEIM P et al: Combination therapy with colestipol and psyllium mucilloid in patients with hyperlipidemia. Ann. Int. Med. (1995) 123:493–499.
  • DAVIDSON MH, DILLON MA, GORDON B, JONES P et al: Colesevelam hydrochloride (cholestagel). A new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch. Intern. Med. (1999) 159:1893–1900.
  • ••Dosing study of colesevelam in patients with hypercholes-terolaemia that demonstrated dose-dependent decreases in LDL-cholesterol.
  • HELLER D, STEVENS RE, DAVIDSON D, DONOVAN J, BURKE S: Absorption of 14C-colesevelam hydrochlo-ride in healthy male and female volunteers. Pharm. Sci. (1999) 1:4085.
  • MESNER CH, BURKE SK, OLSON T: Effect of cholestageland lovastatin alone and in combination for the treatment of hypercholesterolemia. Xfi International Symposium on PALM (1998):60.
  • INSULL I, TOTH P, MULLICAN W et al: Cholestagel, a novel, highly potent, polymeric bile acid sequestrant significantly lowers LDL cholesterol. J. Am. Coll. Cardiol. (2000) 35:258A.
  • ••Abstract report of study substantiating dose-dependentdecreases in LDL-cholesterol.
  • DAVIDSON M, HUNNINGHAKE D, OLSON T, DONOVAN J, BURKE S: Colesevelam HC1 (WelChol), a new, potent, well tolerated, non-systemic lipid-lowering agent. Atherosclerosis (2000)151:130.
  • •Abstract report summarising data from several trials.

Websites

  • http : //www. americanheart . org/statistics/biostats/bioch AMERICAN HEART ASSOCIATION: Cholesterol and Other lipids.
  • http://www.fda.gov/cder/ approval/index GELTEX PHARMACEUTICALS, INC.: NDAs 21–141 /21-176 WelcholmiTablets Package Insert.
  • ••Draft package labelling insert for WelCholl'.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.